Appendix 4C and Quarterly Activities Report - June 2023
Filed with ASX · · 8 pages · English
Genetic Technologies Limited on 6ix
Story so far
Earlier from Genetic Technologies
- Publication Validates geneType for Melanoma Risk Assessment
- Appendix 4C & Quarterly Activities Report - March 2023
- Publication Validates geneType Prostate Cancer Risk Test
- GeneType MultiTest Panel Expanded Inclusion of New Diseases
- Further Study Validates geneType Breast Cancer Risk Test
Later from Genetic Technologies
- Updated Investor Presentation - August 2023
- 2023 Annual Report and Appendix 4E
- Annual Results Momentum Building on our Commercial Plans
- geneType Granted Approval for 3 New Diseases in Australia
- MRFF Grant Names GTG as Sole Industry Partner
Follow Genetic Technologies into a list and get an email when it puts out news.
Follow Genetic Technologies